SGLT-2 inhibitors, such as dapagliflozin, canagliflozin, empagliflozin and ipragliflozin, downregulates the reabsorption ability while increases urinary excretion of glucose in patients with T2DM [60]. The gene discussed is SLC5A2; the disease is type 2 diabetes mellitus.